GlaxoSmithKline CEO Andrew Witty

Andrew Witty, GlaxoSmithKline CEO

GlaxoSmithKline appointed Andrew Witty to succeed Jean-Pierre Garnier as CEO. He took over in may. Witty has spent his entire career at Glaxo, with stints in South Africa, the U.S., and Asia. He was previously president of the company's European pharma division.

Suggested Articles

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.